OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Swissmedic grants conditional marketing authorization for Novavax COVID-19 vaccine for individuals aged 18 years or older in Switzerland.
Novavax announced on April 13, 2022 that its COVID-19 vaccine Nuvaxovid has been granted conditional marketing authorization by Swissmedic, the Swiss Agency for Therapeutic Products, for active immunization to prevent COVID-19 in individuals aged 18 years or older. The vaccine will be the first protein-based COVID-19 vaccine authorized for use in Switzerland.
Novavax previously had an agreement with the government of Switzerland for up to six million doses of Novavax’ COVID-19 vaccine. The vaccine is a protein-based vaccine created using Novavax’ recombinant nanoparticle technology. Novavax has established partnerships for the manufacture, commercialization, and distribution of its vaccine worldwide. Existing authorizations leverage the company’s manufacturing parentship with Serum Institute of India, the world’s largest vaccine manufacturer by volume.
"We are proud that Switzerland is part of the growing list of countries to authorize Nuvaxovid and that people in Switzerland will have a protein-based COVID-19 vaccine option," said Stanley C. Erck, President and CEO of Novavax. "As we continue to fight COVID-19, we think it is incredibly important that people have a choice in vaccine options. Nuvaxovid offers something different from the current portfolio of vaccines by using a more tried and tested technology platform, while still providing a strong efficacy and safety profile."